Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 3 1

Status

Withdrawn 1Completed 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2

Conditions

Peripheral Nervous System Diseases 2Multiple Myeloma 2Lymphoma, Large B-Cell, Diffuse 2Lymphoma 2Colorectal Neoplasms 2Wilms Tumor 1Sarcoma 1Recurrence 1Prostatic Neoplasms 1Oral Complications 1Neurotoxicity Syndromes 1Neuroectodermal Tumors, Primitive, Peripheral 1Neoplasms, Plasma Cell 1Neoplasm Metastasis 1Multiple Endocrine Neoplasia Type 1 1Lymphoma, T-Cell 1Lymphoma, Extranodal NK-T-Cell 1Leukemia 1Kidney Neoplasms 1Hodgkin Disease 1Dendritic Cell Sarcoma, Interdigitating 1Burkitt Lymphoma 1Breast Neoplasms 1

Interventions

Bevacizumab 234Fluorouracil 220Oxaliplatin 216Irinotecan 215Leucovorin 199Capecitabine 153Cetuximab 146Panitumumab 70Folfox protocol 51regorafenib 43Radiotherapy 38pembrolizumab 37IFL protocol 36HMPL-013 36trifluridine tipiracil drug combination 32Nivolumab 32Drug Therapy 26Neoadjuvant Therapy 24Trifluridine 18Celecoxib 18tislelizumab 17XELOX 17sintilimab 16Trastuzumab 16durvalumab 15atezolizumab 15aflibercept 15Chemotherapy, Adjuvant 15Biopsy 15apatinib 14

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Colorectal Neoplasms × Glutamine × Clear all
NCT00255229 2016-02-25

Study of Glutamine as Prophylaxis for Irinotecan Induced Diarrhea

AHS Cancer Control Alberta

Phase 2 Completed
130 enrolled
Gastrointestinal

Colorectal Neoplasms

NCT01157039 2016-02-24

A Trial of Glutamine to Prevent Oxaliplatin Neurotoxicity and a Pharmacokinetic Analysis of Oxaliplatin

AHS Cancer Control Alberta

Phase 2 Withdrawn
Gastrointestinal

Neoplasm Metastasis, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡